Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

P2a INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Primary Completion: December 30, 2021 => June 30, 2022 [Anticipated]
Study Completion: December 30, 2021 => June 30, 2022 [Anticipated]
Study Start: May 24, 2018

Last Update Posted: October 4, 2021 [Actual] => January 18, 2022 [Actual]

Overall Status: Active, not recruiting

https://clinicaltrials.gov/ct2/history/NCT03502785?A=26&B=27&C=merged#StudyPageTop

Primary Outcome Measures :
Number of Adverse Events [ Time Frame: From baseline up to 90 days after last dose of study medication (up to approximately 2 years and 3 months) ]
Antigen-Specific Cellular Immune Response [ Time Frame: At baseline, Weeks 3, 6, 9, 12 and every 12 weeks thereafter up to end of study (up to approximately 2 years) ]
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator Review in Cohort A [ Time Frame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years) ]